NCT06815471 · Corteria Pharmaceuticals
CRF2 Agonist for the Treatment of Worsening Heart Failure
(CRAFT-WHF)
What this study is about
This study assesses the effects of the experimental drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
View original scientific description
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Interventions
DRUG
COR-1167
28-day treatment
DRUG
Placebo
28-day treatment
Primary outcome measures
Natriuresis
Time frame: 24 hours
Urinary sodium excretion
Body weight
Time frame: 7 days
Changes in body weight
NT-proBNP
Time frame: 7 days
Changes in NT-proBNP
Kansas City Cardiomyopathy Questionnaire (KCCQ)-Total Symptom Score (TSS)
Time frame: 28 days
Changes in KCCQ-TSS - The score ranges from 0 to 100 with higher score indicating a better health status
Left Atrial Volume index (LAVi)
Time frame: 2 days
Changes in LAVi - LAV-i is an index of cardiac function measured by echocardiogram
Who can participate
This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.
Inclusion criteria
- Signed written informed consent
- Previous diagnosis of HF documented in source records and confirmed by investigator assessment (no historical written documentation required)
- Prescribed an oral loop diuretic for at least 1 month preceding the index event
- NT-proBNP ≥300 pg/mL or BNP ≥100 pg/mL
- Requires treatment with i.v. diuretics for volume overload
- At least 1 risk factor for diuretic resistance
- Admitted to the hospital not more than 120 hours prior to randomization
Exclusion criteria
- Index event primarily triggered by an acute event (e.g. AMI, PE, arrhythmia)
- Administration of i.v. inotropic therapy or i.v. vasodilators, use of mechanical ventilation, high-flow oxygen therapy, or NIV prior to randomization
- Requirement for, or planned use of LVADs, IABP, or any type of MCS
- History of solid organ transplant or active on a transplant list
- SBP \<100 mmHg
- eGFR \< 20 mL/min/1.73 m2
- CABG, PCI, implantation of CRT, heart valve procedure or any cardiac surgery within 1 month prior to screening or planned during the study
- Severe stenotic cardiac valvular disease
- Severe chronic pulmonary disease requiring chronic steroid therapy or chronic oxygen therapy (\> 2 L/min)
- Uncorrected severe hyperthyroidism or hypothyroidism
- Severe restrictive, obstructive, or infiltrative cardiomyopathy
- Body weight \< 70 kg at screening
- Use of any investigational drug(s) within 5 half-lives of screening
- At high risk of death, defined as life expectancy ≤1 year (such as participants in potential impending cardiogenic shock), or any disease that, in the opinion of the Investigator, will preclude their safe participation in this study, and will make implementation of the protocol or interpretation of the study results difficult
- Presence of any other conditions (e.g. geographic, social) actual or anticipated, that the Investigator feels would restrict or limit the subject's participation or compliance with all study procedures
- Participant is the Investigator or any Subinvestigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study
- Increased lactate levels \> upper limit of normal (local laboratory) at screening
- Severe chronic liver disease (such as cirrhosis)
Where
- Indianapolis, Indiana
- Detroit, Michigan
- Greensboro, North Carolina
- Raleigh, North Carolina
- Columbus, Ohio
- Oklahoma City, Oklahoma
Collaborators
Worldwide Clinical Trials
Related conditions & keywords
Frequently asked questions
What is a clinical trial?
A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.
Is it safe to participate?
Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.
Will I be compensated?
Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.
Will I receive a placebo instead of treatment?
When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.
Can I leave a trial if I change my mind?
Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.
How long does a clinical trial last?
Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.
Data: ClinicalTrials.gov · synced Nov 16, 2026 · Source of record for eligibility and locations